Joshua F Baker1,2,3, Patricia Katz4, David R Weber5, Patrick Gould2, Michael D George2, Jin Long6, Babette S Zemel5, Jon T Giles7. 1. Philadelphia VA Medical Center, Philadelphia, PA, USA. 2. University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 3. Department of Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA. 4. University of California San Francisco, San Francisco, CA, USA. 5. Children's Hospital of Philadelphia, Philadelphia, PA, USA. 6. Stanford University, Palo Alto, CA, USA. 7. Columbia University, New York, NY, USA.
Abstract
PURPOSE: We determined associations between adipokines and abnormal body composition in patients with rheumatoid arthritis (RA). METHODS: Combining data from three RA cohorts, whole-body dual-energy absorptiometry measures of appendicular lean mass and fat mass indices were converted to age, sex, and race-specific Z-Scores. Lean mass relative to fat mass was determined based on prior methods. Independent associations between body composition profiles and circulating levels of adiponectin, leptin, and fibroblast growth factor(FGF)-21 were assessed using linear and logistic regression models adjusting for demographics and study cohort. We also determined the improvement in the area-under-the-curve (AUC) for prediction of low lean mass when adipokines were added to predictive models that included clinical factors such as demographics, study, and body mass index (BMI). RESULTS: Among 419 participants, older age was associated with higher levels of all adipokines while higher C-reactive protein was associated with lower adiponectin levels and higher FGF-21 levels. Greater fat mass was strongly associated with lower adiponectin levels and higher leptin and FGF-21 levels. Higher levels of adiponectin, leptin, and FGF-21 were independently associated with low lean mass. The addition of adiponectin and leptin levels to regression models improved prediction of low lean mass when combined with demographics, study, and BMI (AUC 0.75 v. 0.66). CONCLUSIONS: Adipokines are associated with both excess adiposity and low lean mass in patients with RA. Improvements in the prediction of body composition abnormalities suggest that laboratory screening could help identify patients with altered body composition who may be at greater risk of adverse outcomes. This article is protected by copyright. All rights reserved.
PURPOSE: We determined associations between adipokines and abnormal body composition in patients with rheumatoid arthritis (RA). METHODS: Combining data from three RA cohorts, whole-body dual-energy absorptiometry measures of appendicular lean mass and fat mass indices were converted to age, sex, and race-specific Z-Scores. Lean mass relative to fat mass was determined based on prior methods. Independent associations between body composition profiles and circulating levels of adiponectin, leptin, and fibroblast growth factor(FGF)-21 were assessed using linear and logistic regression models adjusting for demographics and study cohort. We also determined the improvement in the area-under-the-curve (AUC) for prediction of low lean mass when adipokines were added to predictive models that included clinical factors such as demographics, study, and body mass index (BMI). RESULTS: Among 419 participants, older age was associated with higher levels of all adipokines while higher C-reactive protein was associated with lower adiponectin levels and higher FGF-21 levels. Greater fat mass was strongly associated with lower adiponectin levels and higher leptin and FGF-21 levels. Higher levels of adiponectin, leptin, and FGF-21 were independently associated with low lean mass. The addition of adiponectin and leptin levels to regression models improved prediction of low lean mass when combined with demographics, study, and BMI (AUC 0.75 v. 0.66). CONCLUSIONS: Adipokines are associated with both excess adiposity and low lean mass in patients with RA. Improvements in the prediction of body composition abnormalities suggest that laboratory screening could help identify patients with altered body composition who may be at greater risk of adverse outcomes. This article is protected by copyright. All rights reserved.
Authors: Joshua F Baker; Jon T Giles; David Weber; Mary B Leonard; Babette S Zemel; Jin Long; Said Ibrahim; Patricia P Katz Journal: Rheumatology (Oxford) Date: 2017-06-01 Impact factor: 7.580
Authors: John A Shepherd; Bo Fan; Ying Lu; Xiao P Wu; Wynn K Wacker; David L Ergun; Michael A Levine Journal: J Bone Miner Res Date: 2012-10 Impact factor: 6.741
Authors: Joshua F Baker; Anne B Newman; Alka Kanaya; Mary B Leonard; Babette Zemel; Iva Miljkovic; Jin Long; David Weber; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-16 Impact factor: 6.053
Authors: Jon T Giles; Ashkan A Malayeri; Veronica Fernandes; Wendy Post; Roger S Blumenthal; David Bluemke; Jens Vogel-Claussen; Moyses Szklo; Michelle Petri; Allan C Gelber; Lyndia Brumback; João Lima; Joan M Bathon Journal: Arthritis Rheum Date: 2010-04
Authors: Joshua F Baker; Joan Marie Von Feldt; Sogol Mostoufi-Moab; Woojin Kim; Elena Taratuta; Mary B Leonard Journal: J Rheumatol Date: 2015-09-01 Impact factor: 4.666
Authors: Małgorzata Łączna; Patrycja Kopytko; Marta Tkacz; Katarzyna Zgutka; Michał Czerewaty; Maciej Tarnowski; Dariusz Larysz; Rafał Tkacz; Daniel Kotrych; Katarzyna Piotrowska; Krzysztof Safranow; Karolina Łuczkowska; Bogusław Machaliński; Andrzej Pawlik Journal: J Clin Med Date: 2022-05-12 Impact factor: 4.964